77 research outputs found
A case of xenon inhalation therapy for respiratory failure and neuropsychiatric disorders associated with COVID-19
Acute respiratory distress syndrome (ARDS) is the main danger to the life of patients with pneumonia caused by SARS-CoV-2. At the same time, respiratory failure (RF) after ARDS can persist for a long time despite intensive therapy. Therefore, it is important to develop new effective approaches for restoring the ventilation function of the lungs after COVID-19. Here, we present a case report of effective application of short-term inhalations of xenon-oxygen (Xe/O2) gas mixture for treatment of RF and neuropsychiatric disorders (NPD) associated with COVID-19. The patient inhaled a gas mixture of 70 % Xe and 30 % O2. We used multispiral computed tomog-raphy, evaluated psychometry, studied hematological and biochemical blood parameters, and applied some other methods of clinical studies to assess the therapeutic effectiveness of Xe inhalation. Also, we studied the mecha-nism of action of xenon with computer modeling. The clinical case showed the high efficacy of Xe/O2 mixture for treating severe RF and NPD after SARS-CoV-2 infection. Xenon inhalations dramatically increased oxygen saturation and the degree of pneumatization of the lungs. We found out that in coronavirus pneumonia, saturated phospholipids of surfactant are transferred to the solid-ordered phase, which disrupts the surface tension of the alveoli and alveolar gas exchange. Using molecular modeling methods, we demonstrated that the xenon atom in-creases the distance between the acyl chains of phospholipids due to the van der Waals dispersion interaction. These changes allow for the phase transition of phospholipids from the solid-ordered phase to the liquid phase and restore the functional activity of the surfactant. The findings suggest the feasibility of conducting studies on the effectiveness of Xe/O2 inhalations for treating ARDS in SARS-CoV-2 infection
Global tests evaluating the functional condition of hemostasis
Control of effectiveness of global tests evaluation of the functional state regulation of blood aggregation provided an opportunity to obtain timely information about the I-II and III phases of hemostasis while using native substrate - whole blood. Ex vivo, registered during hemocoagulation of changing the viscous characteristics of whole blood, allowed to formulate the concept of fibrinogenesis permanence as in vivo existing process, defining proper hemostatic potential β integrative characteristic of the entire cycle of hemocoagulation, ensuring necessary blood fluidity and restricting extravasation of its components in case of defecting its permeability or damaging its vascular wall
ENDOTHELIAL PROTECTIVE ACTIVITY OF 2,6-DIISOBORNYL-4-METHYLPHENOL IN A MODEL OF MYOCARDIAL ISCHEMIA/REPERFUSION IN RATS
Objective: Our research focuses on the endothelial protective effects of 2,6-diisobornyl-4-methylphenol. Its effect was revealed while studying rats experiencing myocardial ischemia/reperfusion. The research results demonstrated that there are significant disturbances in the vascular endothelium manifested by a decrease in the vasodilating activity and antiplatelet properties of 2,6-diisobornyl-4-methylphenol.
Methods: We designed our own model of myocardial ischemia/reperfusion and applied it to 52 adult outbred Wistar males. We employed some methods of hemostasiological research such as thromboelastography to determine the antiplatelet activity of the vascular wall, G. Born nephelometric method to study platelet aggregation, phase contrast microscopy to count platelet counts in blood plasma, measurement of intra-arterial pressure to study the endothelial vasodilating function, and calculated the endothelial dysfunction coefficient in rats.
Results: Preventive intragastric injection of 2,6-diisobornyl-4-methylphenol (100 mg/kg, 3 days before and 5 days after reproducing the myocardial ischemia/reperfusion model) increased the antiplatelet activity of the vascular endothelium in rats by 37% compared to the endothelium of the abdominal aorta segment of untreated animals. Moreover, 2,6-diisobornyl-4-methylphenol decreased the endothelial dysfunction coefficient by 43% in comparison with the value in the control group.
Conclusion: 2,6-diisobornyl-4-methylphenol has an endothelial protective effect proved by its ability to increase antiplatelet properties of the endothelium and decrease the endothelial dysfunction coefficient. The revealed endothelial protective properties of 2,6-diisobornyl-4-methylphenol can be regarded as one of the potential mechanisms of cardioprotective activity of the drug
Cerebroprotective and regenerative effects of alkaloid Z77 under conditions of brain ischemia
ΠΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ ΠΏΡΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΡΠΈΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΉ
Surgical thyropathy correction is inevitably accompanied by specific change s in hormonal status. We have analyzed the ada ptation mechan - isms and compensat ory and adaptive reactions responsible for the whole life-support system of organism. On the basis of a number of organism homeostats nonspecific mechanism s of resistant and tolerant realisation strategies of long-term adaptation were studied, suppositions were made on possible effective course of adaptation reactions in the conditions of healthy thyroidal issue transplantation and cellular therapy use.Π₯ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ ΡΠΈΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΉ Π½Π΅ΠΈΠ·Π±Π΅ΠΆΠ½ΠΎ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΠΌΠΈ Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ°. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠΎΡΠΌΠΈΡΡΡΡΠΈΠ΅ΡΡ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΈ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΎΡΠ½ΠΎ-ΠΏΡΠΈΡΠΏΠΎΡΠΎΠ±ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ, ΠΎΡΠ²Π΅ΡΠ°ΡΡΠΈΠ΅ Π·Π° ΡΠΈΡΡΠ΅ΠΌΡ ΠΆΠΈΠ·Π½Π΅ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° Π² ΡΠ΅Π»ΠΎΠΌ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΡΠ΄Π° Π³ΠΎΠΌΠ΅ΠΎΡΡΠ°ΡΠΎΠ² ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° ΠΈΠ·ΡΡΠ΅Π½Ρ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΈ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΠΉ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ Π΄ΠΎΠ»Π³ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ, ΡΠ΄Π΅Π»Π°Π½Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π½ΠΈΡ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π·Π΄ΠΎΡΠΎΠ²ΠΎΠΉ ΡΠΈΡΠ΅ΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
A new tecnology of evaluating pharmacodynamics of antiaggregants
Π£ΡΠ°ΡΡΠΈΠ΅ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² Π² Π³Π΅ΠΌΠΎΡΡΠ°Π·Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ, Π±ΡΠ΄ΡΡΠΈ Β«ΡΡΠΈΠ³Π³Π΅ΡΠ°ΠΌΠΈΒ» ΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌΠΈ ΡΡΠ°ΡΡΠ½ΠΈΠΊΠ°ΠΌΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΡΡΠΎΠΌΠ±ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ. Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π°Π½ΡΠΈΠ°Π³ΡΠ΅Π³Π°Π½ΡΠΎΠ² Π½Π° ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ Π°Π³ΡΠ΅Π³Π°ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅ΡΡΠ° Π½ΠΈΠ·ΠΊΠΎΡΠ°ΡΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π·ΠΎΡΡΠΎΠΌΠ±ΠΎΡΠ»Π°ΡΡΠΎΠ³ΡΠ°ΡΠΈΠΈ. ΠΠΎ Π΄Π°Π½Π½ΡΠΌ Β«Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΠΎΠ³ΠΎΒ» ΡΠ΅ΡΡΠ°, Π½Π° Π½Π°ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°ΠΏΠ°Ρ
Π³Π΅ΠΌΠΎΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½ΡΠΈΠ°Π³ΡΠ΅Π³Π°Π½ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ Π±Π»ΠΎΠΊΠ°ΡΠΎΡΠΎΠ² Π¦ΠΠ-1 ΠΈ ΠΠΠ€-ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΡΠΈΠ»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠΌΠ±ΠΈΠ½ΠΎΠ²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π³ΠΈΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ. ΠΠ»ΠΎΠΊΠ°ΡΠΎΡ ΡΠΎΡΡΠΎΠ΄ΠΈΡΡΡΠ΅ΡΠ°Π·Ρ, ΠΈΠΌΠ΅Ρ ΠΌΠ΅Π½ΡΡΠΈΠΉ Π°Π½ΡΠΈΠ°Π³ΡΠ΅Π³Π°Π½ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ, Π² ΠΌΠ΅Π½ΡΡΠ΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠΎΠΌΠ±ΠΈΠ½ΠΎΠ²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ Π³ΠΈΠΏΠΎΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠ΅ΠΉ.Participation of platelets in hemostasis is their main function, as βtriggersβ and at the same time the key participants in the process thrombogenesis. Study the effect of antiplatelet agents on the system of regulation of the state of aggregation of whole blood from healthy volunteers using test low-frequency pyezothromboelastography. According to the βglobalβ test in the initial stages of blood coagulation, pronounced specific antiplatelet effect of blockers of COX-1 and ADP receptor is accompanied by increased thrombin activity and the formation of a hypercoagulable. Blocker of phosphodiesterase having less antiplatelet effect is lesser influence on change in activity of thrombin, followed with anticoagulation
ΠΠΎΠ²Π°Ρ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ (Π΄Π΅ΠΉΡΡΠ²ΠΈΡ) ΠΎΡΠ°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠΎΠ²
Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΏΡΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»ΡΠ΅ΡΡΡ ΡΠ°ΡΠ³Π΅ΡΠ½ΡΠΌ ΠΏΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΡΠΌ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ°ΠΌ, ΠΏΡΡΠΌΠΎΠΌΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΡΠΎΠΌΠ±ΠΈΠ½Π° (ΡΠ°ΠΊΡΠΎΡΠ° IIΠ°) β Π΄Π°Π±ΠΈΠ³Π°ΡΡΠ°Π½Π° ΡΡΠ΅ΠΊΡΠΈΠ»Π°ΡΡ ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠ°ΠΊΡΠΎΡΠ° Π₯Π° β ΡΠΈΠ²Π°ΡΠΎΠΊΡΠ°Π±Π°Π½Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°. Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π°Π»Π³ΠΎΡΠΈΡΠΌΠ° ΠΎΡΠ΅Π½ΠΊΠΈ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π΄Π°Π±ΠΈΠ³Π°ΡΡΠ°Π½Π° ΡΡΠ΅ΠΊΡΠΈΠ»Π°ΡΠ° ΠΈ ΡΠΈΠ²Π°ΡΠΎΠΊΡΠ°Π±Π°Π½Π°, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π½Π° ΠΎΡΠ΅Π½ΠΊΠ΅ Π³Π΅ΠΌΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π° Β«Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΡΠΌΒ» ΡΠ΅ΡΡΠΎΠΌ β Π½ΠΈΠ·ΠΊΠΎΡΠ°ΡΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π·ΠΎΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠ»Π°ΡΡΠΎΠ³ΡΠ°ΡΠΈΠ΅ΠΉ, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠΈΠΌ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ, Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΡ, ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ, Π½Π°Π΄Π΅ΠΆΠ½ΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° Π³Π΅ΠΌΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π° Β«Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΡΠΌΒ» ΡΠ΅ΡΡΠΎΠΌ β Π½ΠΈΠ·ΠΊΠΎΡΠ°ΡΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π·ΠΎΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠ»Π°ΡΡΠΎΠ³ΡΠ°ΡΠΈΠ΅ΠΉ β ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ, Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΡ, ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ, Π½Π°Π΄Π΅ΠΆΠ½ΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π½ΠΈΠ·ΠΊΠΎΡΠ°ΡΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π·ΠΎΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠ»Π°ΡΡΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π° Π΄Π»Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².Currently, attention is paid to βtargeted, oralβ anticoagulants, direct thrombin inhibitors (IIa factor) β Dabigatran etexilate and Xa inhibitor factor β Rivaroxaban and control methods for their influence on the hemostatic system. The aim of this study was to develop an algorithm estimates the anticoagulant dabigatran etexilate and action Rivaroxaban based on an assessment of the hemostatic potential βglobalβ test β the low-frequency piezoelectric thromboelastography ensuring efficiency, availability, informative, reliability studies. Assessment of hemostatic potential βglobalβ test β low-frequency pyezoelectric thromboelastography provides efficiency, availability, informative, reliability studies. Low-frequency piezoelectric thromboelastography indicators dynamics can be used to monitor the anticoagulant effect of drugs
- β¦